AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.7575
-0.0025 (-0.14%)
As of 10:41AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.7600
Open1.7900
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.7500 - 1.8200
52 Week Range0.3800 - 4.9500
Volume115,050
Avg. Volume763,856
Market Cap151.709M
Beta1.16
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire15 days ago

    Ampio Provides Scientific Update and Links to Peer Review Publications

    ENGLEWOOD, Colo., June 5, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced two peer-reviewed articles on the clinical application of Ampion™ are now available online. "Peer-reviewed journals are an important part of the scientific process, which requires intensive scrutiny by other experts in the field of any manuscript submitted before publication. Ampion™ is the 'Low Molecular Weight Fraction of 5% human serum Albumin' (LMWF-5A) that is in development to treat severe osteoarthritis of the knee (OAK).

  • PR Newswire22 days ago

    Ampio Updates Regulatory and IP Activities

    The Company and the FDA have agreed to a July 2018 meeting to continue their discussions on the BLA submission being prepared for Ampion™ as a treatment of the signs and symptoms of severe (KL4) osteoarthritis-of-the- knee (OAK). Ampio was awarded US patent (9,956,217 B2) titled: "Treatment of Joint conditions" that provides method protection, until the year 2035, for multiple injections of Ampion™. This is supported by the fully enrolled Open-Label Extension (OLE) study for the assessment of the clinical safety for long-term treatment with Ampion (up to 5 yearly injections) that will conclude in 2019 and the completed (published) 3 injections trial (STRUT or AP-007).

  • ACCESSWIRE28 days ago

    Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • PR Newswire29 days ago

    Ampio Updates Scientific presentations and publications on Ampion™

    ENGLEWOOD, Colo., May 22, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a poster presentation on the mechanism of action of a component of Ampion™ will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been accepted for publication by PSS.

  • PR Newswirelast month

    Ampio Provides Corporate Update

    During Q1, the Company received a total of $3.1 million from investor warrants and stock options being exercised. Discussions with the FDA are ongoing to address FDA questions and provide the company's responses, as the Agency encourages companies to discuss all facets of regulatory filing, including clinical results, labeling, Chemistry, Manufacturing and Controls (CMC), and other aspects of the development process prior to filing their BLA in order to reduce the possibility of receiving a Refusal to File (RTF) notification.

  • PR Newswire2 months ago

    The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal

    ENGLEWOOD, Colo., May 2, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the publication entitled: "Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial" authored by Dr. Brian Cole, MD, Kristin Salottolo MPH and Dr. David Bar-Or, MD was accepted for publication to the peer-reviewed journal "Patient Safety in Surgery".

  • PR Newswire2 months ago

    Ampio Updates Regulatory, Clinical and NYSE Activities

    ENGLEWOOD, Colo., April 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has begun preliminary discussions with the Food and Drug Administration on details of the Biologics License Application (BLA) submission process for Ampion™, a treatment for severe osteoarthritis-of-the-knee. Second, Nature Biotechnology, a respected journal, with a very high impact factor, has published a commentary on Ampion, our lead drug. Finally, Ampio has received a notification letter from the New York Stock Exchange confirming that Ampio is now in full compliance with their listing requirements.

  • PR Newswire3 months ago

    Ampio Updates Regulatory and Clinical Activities

    ENGLEWOOD, Colo., April 3, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has retained PAREXEL® (www.parexel.com/) to assist in preparing and presenting the Biologics License Application (BLA) for Ampion™ for the treatment of osteoarthritis-of-the-knee (OAK) to the FDA. Mr. Macaluso, Ampio's CEO, noted that "PAREXEL is particularly suited to assist the Company in the preparation and presentation of the BLA to the FDA because their CRO Division helped design and manage the successful pivotal Phase III clinical trial.

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Apple Hospitality REIT, J.Jill, Benefitfocus, Ampio Pharmaceuticals, MFA Financial, and Del Frisco's Restaurant Group — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswire3 months ago

    Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections

    ENGLEWOOD, Colo. , March 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced partial results of a follow-up (3.4-3.7 years), double-blind, randomized, controlled trial ...

  • PR Newswire3 months ago

    Ampio Pharmaceuticals Provides Corporate Update Following Conference Call

    Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K. Primary endpoint achieved statistical significance when 71% of Ampion-treated patients met the OARSI responder criteria, which exceeded the historically based standard control for a meaningful treatment in severe OAK (p

  • PR Newswire3 months ago

    Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST

    ENGLEWOOD, Colo. , March 6, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) hosting a conference call Wednesday, March 7th at 5:00 pm EST . Participants are invited to dial in using ...

  • PR Newswire5 months ago

    Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions

    ENGLEWOOD, Colo., Jan. 16, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharmaceutical companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017. The discussions also explored whether Ampion™ could provide not only relief of signs and symptoms of osteoarthritis of the knee (OAK) but also be "a disease-modifying drug" for this condition. David Bar-Or, M.D., Ampio's CSO explained: "OAK, over time, causes progressive loss of cartilage in the knee, which is one of the reasons for limited joint function and chronic pain in this condition (although cartilage has no nerve endings, sub chondral bone does).

  • PR Newswire5 months ago

    Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders

    ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...

  • Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)
    PR Newswire6 months ago

    Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

    ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis

    NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...

  • PR Newswire7 months ago

    Ampio Pharmaceuticals Announces Engagement of LaVoieHealthScience for Integrated Public and Investor Relations

    ENGLEWOOD, Colo., Nov. 30,  2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the engagement of LaVoieHealthScience for their services in investor and public relations. LaVoieHealthScience, an integrated investor and public relations agency focused on advancing health and science innovations, will be supporting Ampio in their strategic communications with a broad range of audiences including media, healthcare professionals, the investment community and others.  LaVoieHealthScience will use their 16 years of proven industry tactics to help Ampio extend visibility and optimize value.

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Agenus Inc.

    NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat ...

  • PR Newswire7 months ago

    Ampio Announces Publication of Ampion™ Treatment of Severe Osteoarthritis of the Knee as a Feature Article in Orthopedics Peer-Reviewed Journal

    The article describes the efficacy and safety of Ampion™ (LMWF-5A) in an integrated analysis of three single injection randomized controlled studies of severe osteoarthritis of the knee (Kellgren-Lawrence [KL] grade 4 disease).

  • PR Newswire7 months ago

    Ampio Pharmaceuticals, Inc. Announces Continued Listing Plan Accepted by NYSE American

    ENGLEWOOD, Colo., Nov. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio" or the "Company") today announced the receipt of notification that the Company's plan to regain compliance with the NYSE American's continued listing standards has been accepted by the NYSE American LLC ("NYSE American"). As previously reported by the Company in a Current Report on Form 8-K on September 7, 2017, the Company received a letter from the NYSE American on September 1, 2017 stating that the Company was not in compliance with the continued listing standards of the NYSE American Company Guide (the "Company Guide") relating to stockholders' equity.

  • PR Newswire7 months ago

    Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion™ in Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Nov. 15, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the beginning of an Open Label Extension (OLE) study of Ampion™ in patients with severe osteoarthritis of the knee (OAK). The OLE study offers patients an opportunity to receive repeat injections of Ampion™ after they have completed the pivotal clinical trial. Ampion™ is the low molecular weight fraction of pharmaceutical 5% human serum albumin (HSA).

  • PR Newswire8 months ago

    Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio") today announced that it has closed it's previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75 million. The sale of the common stock was offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement was filed with the SEC and forms a part of the effective registration statement.

  • PR Newswire8 months ago

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.75 million of shares of common stock at a purchase price of $0.875 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial. Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. are acting as placement agents for the offering.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc.

    NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Shares of both Ampio Pharmaceuticals (NYSE American: AMPE ) and Ardelyx Inc. (NASDAQ: ARDX ) soared on Thursday after both companies had data news, respectively. ...